Clinical significance of KAI1/CD82 protein expression in nasopharyngeal carcinoma

Wang,Gengming; Jiang,Hao; Xu,Hongbo; Sun,Qian; Zhou,Yan; Xiang,Ping; Cheng,Zenong; Zhang,Yajun; Zhou,Yufu; Guo,Qing; Du,Xinglong; Xu,Shuxiu; Ma,Shiyin; Chen,Zhendong

doi:10.3892/ol.2015.2891

Clinical significance of KAI1/CD82 protein expression in nasopharyngeal carcinoma

Authors:
- Gengming Wang
- Hao Jiang
- Hongbo Xu
- Qian Sun
- Yan Zhou
- Ping Xiang
- Zenong Cheng
- Yajun Zhang
- Yufu Zhou
- Qing Guo
- Xinglong Du
- Shuxiu Xu
- Shiyin Ma
- Zhendong Chen
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China, Department of Radiotherapy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Central Laboratory, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Radiotherapy, Taizhou People's Hospital, Taizhou, Zhejiang 225300, P.R. China, Department of Radiotherapy, The Second People's Hospital of Chuzhou, Chuzhou, Anhui 239000, P.R. China, Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Published online on: January 23, 2015 https://doi.org/10.3892/ol.2015.2891
Pages: 1681-1686

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate KAI1/CD82 protein expression in human nasopharyngeal carcinoma (NPC) cell lines and human NPC tissues. Immunohistochemistry and western blot analysis were used to detect the localization and expression levels of the KAI1/CD82 protein in five human NPC cell lines. Immunohistochemistry was also conducted to detect the expression of the KAI1/CD82 protein in 70 NPC tissues and 30 non‑neoplastic nasopharyngeal tissues. The levels of KAI1/CD82 protein expression were found to decrease as the metastatic potential of cells increased. The expression rate of KAI1/CD82 protein in the NPC tissues (44.3%) was significantly lower than that in the non‑neoplastic nasopharyngeal tissues (70.0%) (P<0.05). KAI1/CD82 protein expression in the NPC tissues was not associated with clinical parameters, including gender, age, histological type and T stage, and the positive expression of KAI1/CD82 decreased with increased N staging. The level of KAI1/CD82 protein expression was increased in different human NPC cell lines. The KAI1/CD82 gene was highly expressed in cells with low metastatic potential, while low expression was observed in cells with a high metastatic potential. In addition, the KAI1/CD82 gene was expressed at low levels in nasopharyngeal carcinoma tissues, while high expression was identified in non‑neoplastic nasopharyngeal tissues, and was associated with lymph node metastasis. These results indicated that the KAI1/CD82 gene may be involved in the occurrence, development and metastasis of nasopharyngeal carcinoma.

View Figures

View References

1	Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
2	Siddique MA, Sabur MA, Kundu SC, et al: Difficulty in diagnosis of nasopharyngeal carcinoma. Mymensingh Med J. 21:158–161. 2012.PubMed/NCBI
3	Dong JT, Lamb PW, Rinker-Schaefer CW, et al: KAI-1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science. 268:884–886. 1995. View Article : Google Scholar : PubMed/NCBI
4	Takeda T, Hattori N, Tokuhara T, et al: Adenoviral transduction of MRP-1/CD9 and KAI-1/CD82 inhibits lymph node metastasis in orthotropic lung cancer model. Cancer Res. 67:1744–1749. 2007. View Article : Google Scholar : PubMed/NCBI
5	Teo PM, Leung SF, Yu P, Tsao SY, Foo W and Shiu W: A comparison of Ho’s, International Union Against Cancer, and American Joint Committee stage classifications for nasopharyngeal carcinoma. Cancer. 67:434–439. 1991. View Article : Google Scholar : PubMed/NCBI
6	Brierly JD, Catton PA, O’Sullivan B, et al: Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center. J Clin Oncol. 20:413–419. 2002. View Article : Google Scholar
7	Tsutsumi S, Shimura T, Morinaga N, et al: Loss of KAI-1 expression in gastric cancer. Hepatogastroenterology. 52:281–284. 2005.PubMed/NCBI
8	Yang X, Wei LL, Tang C, Slack R, Mueller S and Lippman ME: Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res. 61:5284–5288. 2001.PubMed/NCBI
9	Huang CI, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M: Correlation of reduction in MRP-l/CD9 and KAIl/CD82 expression with recurrences in breast cancer patients. Am J Pathol. 153:973–983. 1998. View Article : Google Scholar : PubMed/NCBI
10	Takaoka A, Hinoda Y, Sato S, Itoh F, Adachi M, Hareyama M and Imai K: Reduced invasive and metastatic potentials of KAI-1 transfected melanoma cells. Jpn J Cancer Res. 89:397–404. 1998. View Article : Google Scholar : PubMed/NCBI
11	He B, Liu L, Cook GA, et al: Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. J Biol Chem. 280:3346–3354. 2005. View Article : Google Scholar
12	Charrin S, Manie S, Oualid M, et al: Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation. FEBS Lett. 516:139–144. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zhou B, Liu L, Reddivari M and Zhang XA: The palmitoylation of metastasis suppressor KAI-1/CD 82 is important for its motility-and invasiveness-inhibitory activity. Cancer Res. 64:7455–7463. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ito Y, Yoshida H, Uruno T, et al: KAI-1 expression in tlyroidneoplasmg: its linkage with clinic opathologic features in papillary carcinoma. Pathol Res Pract. 199:79–83. 2003. View Article : Google Scholar
15	Chen Z, Mustafa T, Trojanowicz B, et al: CD82 and CD63 in thyroid cancer. Int J Mol Med. 14:517–527. 2004.PubMed/NCBI
16	Liu FS, Dong JT, Chen JT, et al: KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer. Clin Cancer Res. 9:1393–1398. 2003.PubMed/NCBI
17	Lijovic M, Somers G and Frauman AG: KAIl/CD82 Protein expression in primary prostate cancer and in BPH associated with cancer. Cancer Detect Prev. 26:69–77. 2002. View Article : Google Scholar
18	Christgen M, Bruchhardt H, Ballmaier M, et al: KAI-1/CD82 is a novel target of estrogen receptor-mediated gene repression and down regulated in primary human breast cancer. Int J Cancer. 123:2239–2246. 2008. View Article : Google Scholar : PubMed/NCBI
19	Christgen M, Christgen H, Heil C, et al: Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer, Inhibitory effect of KAI-1 gene on breast cancer cell growth in vitro. Cancer Sci. 100:1767–1771. 2009. View Article : Google Scholar : PubMed/NCBI
20	Malik FA, Sanders AJ, Kayani MA and Jiang WG: Effect of expressional alteration of KAI-1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genomics Proteomics. 6:205–213. 2009.PubMed/NCBI
21	Zhang BH, Liu W, Li L, et al: KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 14:3521–3526. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ma ZB, Li K, Wang J and Guo GH: Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population. Med Oncol. 30:668–672. 2013. View Article : Google Scholar : PubMed/NCBI
23	Knoener M, Krech T, Puls F, et al: Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer. Dis Markers. 32:337–342. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jiang WX, Song BG and Wang PJ: Expression of nm23, KAI1 and spiral computed tomography findings in primary gallbladder carcinoma. Chin Med J. 122:2666–2668. 2009.PubMed/NCBI
25	Guo C, Liu QG, Zhang L, Song T and Yang X: Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 8:389–396. 2009.PubMed/NCBI
26	Yusenko MV and Kovacs G: Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma. Histopathology. 55:687–695. 2009. View Article : Google Scholar : PubMed/NCBI
27	You J, Madigan MC, Rowe A, et al: An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines. Urol Oncol. 9:1324–1330. 2010.
28	Lee HA, Park I, Byun HJ, et al: Metastasis suppressor KAI1/CD82 attenuates the matrix adhesion of human prostate cancer cells by suppressing fibronectin expression and β1 integrin activation. Cell Physiol Biochem. 27:575–586. 2011. View Article : Google Scholar